Wachstumsstarkes Pharmaunternehmen mit KGV 4,4 !! - 500 Beiträge pro Seite

[bootsmann0810]

Wertpapier: CHINA Yongxin Pharmaceuticals...ich bin seit über 10 Jahren an der Börse und meines Erachtens findet man selten so eine Perle: 1. Revenues: 2008: 59,1 Mio 2009: 47,6 Mio = - 19,5 % (enttäuschend ??? ... schaut weiter!!
2 .net-income: 2008: 4,1 Mio 2009: 5,1 Mio + 26 %

3. earnings per share: 2008: 0,13 $ 2009: 0,15 $ und jetzt der Aktienkurs: 0,68 $ !!! - das bedeutet ein KGV von 4,5!!!

ausgegebene Aktien: 35 Mio x 0,68 $ = 23,8 Mio Marktkapitalisierung!!

Ferner charttechnischer Ausbruch bei 0,70 $!! Ich habe viele Seiten recherchiert und gekauft - für mich ein modernes Geschäftsmodell und einer enormen Wachstumsperspektive. Im August letzten Jahres hat die chinesische Regierung eine Liste von 300 Medikamten herausgegeben, die staatlich gefördert werden! 295 ! dieser Medikamente werden von China Yongxin vertrieben!! Klarer Kauf mit Chance auf 300 % in 2010!! Keine Kaufempfehlung - nur meine Meinung, die ich mir aus über 4 Stunden Recherchearbeit bilden konnte!

Weiter Info´s folgen...

[bootsmann0810]

CHINA YONGXIN PHARMACEUTICALS REPORTS A 26% INCREASE IN NET INCOME FOR THE 2009 FISCAL YEAR
4/6/2010 8:00 AM - PR Newswire

Year-end Reflects 37% Gross Profit Increase and Higher Gross Margins in Line With Refocus of Strategy Aimed at Higher Profit Retail Activities

CHANGCHUN, China and LOS ANGELES, April 6, 2010 /PRNewswire via COMTEX News Network/ --
China Yongxin Pharmaceuticals, Inc. (OTC Bulletin Board: CYXN) (the "Company" or "China Yongxin"), a fast-growing vertically-integrated health products company in China, announced today its financial results for the fourth quarter and for the year ended December 31, 2009.

Net income increased to $5.1 million in 2009, a 26% increase over $4.1 million in 2008. The increase was primarily related to higher margin sales and was largely due to an increase in gross profit resulting from a change in the composition of products sold, specifically, an increase in retail product sales.

Revenues for the year ended 2009 decreased to $47.6 million, or 19.5% from $59.1 million for 2008. The decrease in total revenue was due to the transition of the Company's sales strategy, which, because of the uncertain direction of the National Medical Policy, had been refocused from the wholesale business to the retail and medical facilities sector. Although a broader product portfolio and expanded marketing activities increased 2009 revenues from the Company's retail drug stores by approximately 27.9% over the prior year, it was not sufficient to completely offset a decrease in revenue from the Company's wholesale business, resulting in comparably lower total net revenue. The substantial increase in revenue from the retail segment was attributable to the addition of seven new retail drugstores in 2009, all located in prime locations in the center of cities in Jilin province. To further its new retail oriented sales strategy, the Company recently announced its plan to open 28 new retail stores in 2010.

The Company also reported that basic and diluted earnings per share increased to $0.15 for the year ended December 31, 2009 compared to $0.13 for 2008, based on 35.1 million and 31.2 million diluted weighted average shares outstanding for 2009 and 2008, respectively, and 33.2 million and 31.2 million basic weighted averages shares outstanding for 2009 and 2008, respectively. These shares do not include approximately 1.67 million shares of preferred stock owned by management, which is convertible into 10 million shares of common stock.

The cost of goods sold for the year was $31.3 million, a significant reduction compared to $47.2 million in the prior year. The decrease corresponded with a decrease in sales volume. However, the Company was able to reduce the cost of sales to net sales percentage from approximately 80% in 2008 to 66% in 2009 due to a change in product mix in which the proportion of products sold with higher profit margins increased, such as cosmetics and certain health and nutritional products. The Company improved its gross profit margin by approximately 37.2% from $11.9 million in 2008 to $16.3 million in 2009. The increase in gross margins was primarily due to higher margin retail and medical facilities sales.

Operating expenses for 2009 were $7.1 million, compared to $6.0 million in 2008. Selling expenses remained at approximately the same level, at $3.5 million. Management believes that in 2009 the Company prudently managed utilities usage, transportation costs and sales people to effectively reduce selling expenses and maintain its gross profit. General and administrative expenses for 2009 increased approximately 43.0% to $3.6 million, compared to $2.5 million in 2008. The majority of the increase was related to litigation which was recently concluded.

Income from operations for 2009 was approximately $9.2 million, an increase from the $5.9 million for 2008. Operating margins were 18% and 9.8% for 2009 and 2008, respectively. A substantial portion of the increase resulted from the expansion of the hospital market business and the increase of the sale of the health care, cosmetic and nutrition products as well as medical facilities sales.

Mr. Yongxin Liu, Chairman and Chief Executive Officer of the Company, commented, "During 2007, the Company anticipated potential impact on its wholesale distribution business resulting from uncertainty created by the proposed National Medical Policy. We were pleased that the Chinese government's August 18th issuance of China's Essential Drug List (the "EDL") included over 300 commonly used pharmaceuticals that will be subsidized by the government to provide easier access to all citizens. The Company is a retailer or distributor of 295 of the products on the EDL. We continue to be encouraged by the government's successful effort toward healthcare reform and efforts to boost domestic spending."

Mr. Liu also added, "Our income growth in 2009 indicates that our business model has placed the Company in a strong position to take positive advantage of increased government support of health care and the continued expansion of the economy in China." On March 9 2009, China Yongxin once again demonstrated its "state-of-the-art" approach to providing retail drug customers with a high level of service by formally launching its proprietary Electronic Diagnosis System (the "System"), of which 20 Systems have been installed so far in chain drugstores located in Changchun, Jilin. This proprietary system enables our customers to remotely receive medical diagnosis and conveniently purchase prescription drugs at that store. The Company continues to improve the level of service it offers and leverage its large and growing base of customers who opt in as drugstore "members" and who are then entitled to discounts, rebates and special offers. This strategy, in addition to selling a broader array of higher margin health, beauty and cosmetic products has increased customer retention and improved revenue and profitability in this business segment.

Since the beginning of 2009, China Yongxin has signed 12 exclusive distribution agreements for high margin pharmaceutical products within Jilin province with several well-known pharmaceutical manufacturers including Tianjin Smith Kline and French Laboratories Ltd. As of June 30, 2009, China Yongxin has approximately 216 drugs with exclusive distribution rights in Jilin province. This portfolio is a key component of its long-term growth strategy to leverage the large distribution center and channels established to drive incremental future revenue growth. These agreements are typically one year in duration and are renewable.





(TABLE TO FOLLOW)



China Yongxin Pharmaceuticals, Inc.
Consolidated Statements of Income for the Years Ended December 31, 2009
and 2008

2009 2008
Net Revenues $ 47,589,280 $ 59,116,534
Cost of Goods Sold (31,271,463) (47,226,275)
Gross profit 16,317,817 11,890,259
Operating Expenses:
Selling expenses 3,543,383 3,521,147
General and administrative expenses 3,575,059 2,500,366
Total operating expenses 7,118,442 6,021,513
Income From Operations 9,199,376 5,868,745
Other Income (Expense):
Other income 278,846 690,516
Other expense (137,849) (152,469)
Interest income (expense) 9,173 (6,679)
Total other income 150,170 531,368
Operating Income Before Income Tax and
Non controlling Interest 9,349,545 6,400,113

Provision for income tax (2,594,483) (1,009,643)

Net Income Before Non controlling
Interest and Discontinued operations 6,755,062 5,390,470

Loss from discontinued operations (30,951) (84,850)

Net Income Before Non controlling
Interest 6,724,111 5,305,619

Non controlling interest (1,599,122) (1,239,480)
Net Income 5,124,989 4,066,139
Other Comprehensive Item:
Foreign exchange translation gain 123,209 824,961

Net Comprehensive Income $ 5,248,198 $ 4,891,100
Earnings per share
Basic $ 0.15 $ 0.13
Diluted $ 0.15 $ 0.13
Weighted average number of shares
outstanding
Basic 33,240,797 31,150,819
Diluted 35,070,051 31,150,819

...

[lilie31]

scheint ja interessant zu klingen!

und heute schon plus 10prozent?

nehme mal diesen wert auf die watchlist auf,

dann gucken wir mal.

[MrRipley]

Antwort auf Beitrag Nr.: 39.294.609 von bootsmann0810 am 08.04.10 14:17:19

Dann ist das die BB Aktie

[bootsmann0810]

Antwort auf Beitrag Nr.: 39.296.719 von MrRipley am 08.04.10 18:37:05

...ja komme gerade nach Hause und sehe den schönen Kursanstieg...
Volumen ist auch relativ hoch. Ich denke, dass wir heute über 0,8 $ schliessen werden. Mr. Ripley was heißt "BB"?

[MrRipley]

Antwort auf Beitrag Nr.: 39.298.109 von bootsmann0810 am 08.04.10 21:26:08

Börsenbrief

[1erhart]

Antwort auf Beitrag Nr.: 39.298.154 von MrRipley am 08.04.10 21:34:14

Ne ne Brigitte Bardot oder Boris Becker

[bootsmann0810]

Gestern Schlusskurs 0,79 $! Ausbruch gelungen!
Das Umsatzvolume stieg deutlich an betrug 756.000 shares. Jetzt wartet bei 0,8 noch ein Widerstand, der - bei Überwindung - dann die Aktie zum Fliegen bringen dürfte!
Vorher dürfte die Aktie jedoch vielleicht noch einmal auf 0,72 - 0,76 $ zurückfallen unter geringen Umsätzen. Ich bin sehr gespannt, wann die ersten Börsenblätter diesen soliden und aggressiv wachsenden Substanzwert empfehlen werden... "the street" hat China Yongxin bereits als absolut günstig bewertet!! Hier noch der link zur hp!
http://www.yongxinchina.com/

Erfolgreichen Tag!

[bootsmann0810]

..wie heute Morgen avisiert hat der Kurs bis auf 0,74$ mit sehr geringen Umsätzen abgegeben und sich jetzt wieder auf 0,79$ stabilisiert - mit gerade mal 30000 Aktien. Somit wurde der
16 % Anstieg von gestern bereits verdaut und wir dürften heute m. E. uns zwischen 0,77 und 0,80 $ einpendeln. Der Ausbruch wird dann jedoch nicht mehr lange auf sich warten lassen.. erstes weiteres KZ 1,00 $!

Dies ist keine Kaufempfehlung - nur meine Meinung und ich bin für meine Verhältnisse sehr stark in diesem Wert bereits engagiert!

[bootsmann0810]

Heute geht´s wahrscheinlich nochmal auf das Ausbruchsniveau zurück.. bei 0,7 - 0,73 $ dürfte jedoch Schluss sein. Der Umsatz ist heute ebenfalls gering, sodass m. E. zum Börsenende der Kurs wieder anziehen dürfte...
Ich denke, dass wir schon in der kommenden Woche die 1 $ angreifen
werden! Viel Glück allen!

[bootsmann0810]

...Volatilität läßt grüßen... nochmal 0,59$ realtime-kurs..
habe gerade nochmal nachbestellt .. ...

[MrRipley]

Antwort auf Beitrag Nr.: 39.318.814 von bootsmann0810 am 12.04.10 21:18:29

Nicht gerade vertrauenserweckend, Kursziel 0,20?





http://biz.yahoo.com/e/100412/cyxn.ob8-k.html

Entry into a Material Definitive Agreement, Unregistered Sale


Item 1.01 Entry into a Material Definitive Agreement

On April 9, 2010, China Yongxin Pharmaceuticals Inc. (the "Company") consummated a private placement of its equity securities with certain non-U.S. investors pursuant to a Securities Purchase Agreement for total consideration of $1,178,100. The Company issued to the investors an aggregate 5,890,500 shares of common stock, par value $0.001 per share (the "Common Stock") at a price of $0.20 per share. The investors also received, as a part of the financing, warrants for the purchase of up to an aggregate 5,890,500 shares of our Common Stock at an exercise price $0.50 per share (subject to adjustment for stock splits, recapitalizations and other similar events) exercisable for a period of two years. The Company will use the proceeds of this financing for the payment of auditing expenses, legal fees, operating expenses, supplies, and general working capital. The securities were offered and issued in reliance upon an exemption from registration pursuant to Regulation S of the Securities Act of 1933, as amended (the "Securities Act"). We completed the offering pursuant to Rule 903 of Regulation S of the Act on the basis that the sale of the securities was completed in an "offshore transaction", as defined in Rule 902(h) of Regulation S. We did not engage in any directed selling efforts, as defined in Regulation S, in the United States in connection with the sale of the securities. The investors represented to us that they were not U.S. persons, as defined in Regulation S, and were not acquiring the securities for the account or benefit of a U.S. person. The Securities Purchase Agreements executed between us and the investors included statements that the securities had not been registered pursuant to the Act and that the securities may not be offered or sold in the United States unless the securities are registered under the Act or pursuant to an exemption from the Act. The investors agreed by execution of the Securities Purchase Agreements for the securities: (i) to resell the securities purchased only in accordance with the provisions of Regulation S, pursuant to registration under the Act or pursuant to an exemption from registration under the Act; (ii) that the Company is required to refuse to register any sale of the securities purchased unless the transfer is in accordance with the provisions of Regulation S, pursuant to registration under the Act or pursuant to an exemption from registration under the Act; and (iii) not to engage in hedging transactions with regards to the securities purchased unless in compliance with the Act. All securities issued were endorsed with a restrictive legend confirming that the securities have not been registered under the Act and could not be resold without registration under the Act or an applicable exemption from the registration requirements of the Act. The foregoing summary descriptions do not purport to be complete and are qualified in their entirety by the terms of the Securities Purchase Agreement and Warrant, the forms of which are filed as Exhibit 10.1 and Exhibit 10.2, respectively, to this Form 8-K.

[MrRipley]

Antwort auf Beitrag Nr.: 39.318.888 von MrRipley am 12.04.10 21:27:03

Avg. Diluted Shares Outstanding
2007 - 22
08 - 31
09 - 35
2010 nun 40,89Mio Aktien, bevor das Jahr richtig angefangen hat.
Jetzt verstehe ich auch, warum ein Börsenbrief dahinter covert.

Wenn das so weiter geht, haben wir nix von den Fortschritten und müssen vom Shareholdervalue her dem Management nichts Gutes testieren.!

[bootsmann0810]

Ich konnte leider bislang nicht ausfindig machen aus welchem Motiv
das Management shares zu 0,20 $ durchführt ... 40 Mio shares verwässern doch enorm. Selbst der Vorstand hat Ende letzten Jahres die shares noch zu 0,35 $ bezogen! Dennoch ist der Kurs sensationell stabil geblieben... ich bleibe zunächst drin und setze mir einen mentalen Stoppkurs. [/ Sollte kein Verkaufsdruck
aufkommen, dürfte die Aktie relativ schnell auf 1 $ zusteuern, da die geschäftlichen Aussichten genial sind!

- stay -

[Marigold]

hi Leute...

Was ist los, schreibt keiner mehr??

seit ihr schon alle raus?


Gerade entdeckt